These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 18577747)

  • 1. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
    Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
    Smith PG; Tanaka H; Chantry A
    Oncotarget; 2012 May; 3(5):518-24. PubMed ID: 22643838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of response to imatinib: mechanisms and management.
    Shah NP
    Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
    Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
    PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia.
    O'Hare T; Eide CA; Deininger MW
    J Natl Cancer Inst; 2008 Jul; 100(13):908-9. PubMed ID: 18577744
    [No Abstract]   [Full Text] [Related]  

  • 15. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
    Samanta AK; Chakraborty SN; Wang Y; Kantarjian H; Sun X; Hood J; Perrotti D; Arlinghaus RB
    Oncogene; 2009 Apr; 28(14):1669-81. PubMed ID: 19234487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.